IQVIA Holdings Inc. (NYSE:IQV – Get Free Report) was the recipient of a significant increase in short interest during the month of July. As of July 31st, there was short interest totalling 2,900,000 shares, an increase of 8.6% from the July 15th total of 2,670,000 shares. Currently, 1.6% of the company’s shares are short sold. Based on an average daily volume of 1,250,000 shares, the short-interest ratio is currently 2.3 days.
IQVIA Stock Up 1.5 %
Shares of IQV stock traded up $3.48 during trading hours on Monday, reaching $243.11. 797,581 shares of the company’s stock were exchanged, compared to its average volume of 1,073,916. The company has a current ratio of 0.85, a quick ratio of 0.85 and a debt-to-equity ratio of 1.80. IQVIA has a 1 year low of $167.42 and a 1 year high of $261.73. The stock has a market cap of $44.32 billion, a PE ratio of 32.78, a PEG ratio of 2.22 and a beta of 1.49. The stock’s fifty day moving average price is $224.68 and its two-hundred day moving average price is $232.13.
IQVIA (NYSE:IQV – Get Free Report) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.07. The firm had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.79 billion. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm’s revenue was up 2.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.22 EPS. Research analysts predict that IQVIA will post 10.24 EPS for the current year.
Institutional Investors Weigh In On IQVIA
Wall Street Analyst Weigh In
IQV has been the subject of several research analyst reports. Argus raised shares of IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. The Goldman Sachs Group assumed coverage on IQVIA in a report on Thursday, June 6th. They issued a “buy” rating and a $270.00 target price for the company. Morgan Stanley lifted their price objective on IQVIA from $270.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, July 23rd. Jefferies Financial Group cut shares of IQVIA from a “buy” rating to a “hold” rating and dropped their target price for the stock from $266.00 to $242.00 in a report on Wednesday, July 24th. Finally, JPMorgan Chase & Co. upped their price target on shares of IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research report on Monday, August 5th. Five research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and an average target price of $265.67.
View Our Latest Analysis on IQV
IQVIA Company Profile
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
See Also
- Five stocks we like better than IQVIA
- Following Congress Stock Trades
- Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- 2 Option Strategies to Maximize Profits in a Bear Market
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Lululemon Stock Gears Up for a Massive Comeback Rally
Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.